Sarepta Shares Community Letter Regarding ELEVIDYS Label Update

November 18, 2025

On November 16, 2025, Sarepta Therapeutics Inc. shared a Community Letter with updates regarding the label for ELEVIDYS, Sarepta’s approved gene therapy for Duchenne muscular dystrophy.

To view Sarepta’s Community Letter, please click here

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open